Please login to the form below

Not currently logged in
Email:
Password:

Bayer’s Barbara Jaszewski joins Lundbeck

She is appointed VP, global pricing and market access

Barbara Jaszewski, LundbeckLundbeck has named former Bayer director Barbara Jaszewski as its new VP, global pricing and market access.

Jaszewski has great experience in this type of role, serving most recently as director of global market access of Bayer Healthcare for the EMEA region and Canada.

This was her most senior role in a ten year career at Bayer that included several years in Canada as director of reimbursement.

Jaszewski has also spent time at GSK, where she was reimbursement strategist.

Lundbeck's senior VP, global product strategy and portfolio development Andrea Eggert commented on the appointment.

He said: “Barbara Jaszewski will play an important role in leading our efforts to further strengthen Lundbeck's commercial business processes, and will help our organisation support future product launches in the best way possible.”

Jaszewski's most pressing task will be to lead the launch of Selincro (nalmefene), which was recently recommended by the European Medicines Agency (EMA) to treat alcohol dependence.

In addition, Lundbeck also has Brintellix (vortioxetine) under review by the EMA, while a once-monthly version of schizophrenia drug Abilify (aripiprazole) is also due to launch during 2013.

14th January 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics